Fig 1.
Cell viability of PC-3, LNCaP and Adcarc1258 after single application of FX-9, azacitidine, DCA, doxorubicin or carboplatin and the combinations.
The results are expressed as a percentage of DMSO-controls and are plotted as mean ± standard deviation (SD) of three independent experiments. Significance of an effect compared to the single application of FX-9, azacitidine, DCA, doxorubicin, carboplatin or control was calculated by the Dunnett’s t-test. *:p<0.05, **:p<0.01, ***:p<0.001, black *: Significant difference between combination and FX-9 single application, colored *: Significant difference between combination and azacitidine, DCA, doxorubicin or carboplatin single application; x:p<0.01, X:p<0.001, black X: significant difference between single application of FX-9 and DMSO-control, colored X: Significant difference between single application of azacitidine, DCA, doxorubicin or carboplatin and DMSO-control.
Table 1.
Bliss evaluation of the results of cell viability of FX-9 combination with azacitidine, DCA, doxorubicin or carboplatin in PC-3, LNCaP and Adcarc1258.
Fig 2.
Cell count of PC-3, Adcarc1258 and LNCaP after application of FX-9, A: Azacitidine and B: Carboplatin and both agents in combination.
The results are expressed as a percentage of DMSO-controls and are plotted as mean ± standard deviation (SD) of three independent experiments. The significance of an effect compared to the single application of FX-9, azacitidine, carboplatin or DMSO-control calculated by Dunnett’s t-test: *:p<0.05, **:p<0.01, ***:p<0.001, x:p<0.01, X:p<0.001.
Fig 3.
A: PC-3 after application of FX-9 and azacitidine, B: Adcarc1258 after application of FX-9 and azacitidine, C: LNCaP after application of FX-9 and carboplatin and D: Adcarc1258 after application of FX-9 and carboplatin. The analysis was carried out via flow cytometry with an annexin and TO-PRO-3 iodide staining. Fractions of necrotic, apoptotic and vital cells served as a percentage of the total amount of cells. The results are plotted as mean ± standard deviation (SD) of three independent experiments. Significance of an effect compared to the single application of FX-9, azacitidine or carboplatin was calculated by the Dunnett’s t-test. Color coding: White: No significant difference to both single applications; yellow: p<0.05 compared to FX-9 single application; blue: p<0.05 compared to azacitidine or carboplatin single application; green: p<0.05 compared to both single applications.
Fig 4.
Cell count of the cell lines PC-3, Adcarc1258 and LNCaP after exposure to DHT for 120 hours. The results are expressed as percentage of EtOH-controls and are plotted as mean ± standard deviation (SD) of three independent experiments. Significance of an effect compared to the EtOH-control was calculated by the students t-test: *:p<0.05.